Analysis of prognostic factors in peripheral T-cell lymphoma: Prognostic value of Serum Albumin and Mediastinal Lymphadenopathy

Leukemia and Lymphoma

Volumn 50, Issue 12, 2009, Pages 1999-2004

  Chihara, Dai ^a   Oki, Yasuhiro ^a   Ine, Shouji ^a   Yamamoto, Kazuhito ^a   Kato, Harumi ^a   Taji, Hirofumi ^a   Kagami, Yoshitoyo ^a   Yatabe, Yasushi ^a   Nakamura, Shigeo ^a,b   Morishima, Yasuo ^a  

^a AICHI CANCER CENTER HOSPITAL   (Japan)

^b NAGOYA UNIVERSITY HOSPITAL   (Japan)

Author keywords

Angioimmunoblastic lymphoma; Mediastinal lymphadenopathy; Peripheral T cell lymphoma; Peripheral T cell lymphoma not otherwise specified; Prognostic factor; Serum albumin

Indexed keywords

ALBUMIN; CISPLATIN; CYCLOPHOSPHAMIDE; CYTARABINE; DEXAMETHASONE; DOXORUBICIN; ETOPOSIDE; HEMOGLOBIN; MEPREDNISONE; PREDNISONE; VINCRISTINE;

ADULT; ALBUMIN BLOOD LEVEL; ANGIOIMMUNOBLASTIC T CELL LYMPHOMA; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; CANCER RADIOTHERAPY; CONTROLLED STUDY; DRUG MEGADOSE; FEMALE; HUMAN; LYMPHADENOPATHY; MAJOR CLINICAL STUDY; MALE; MEDIASTINUM LYMPH NODE; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; PERIPHERAL T CELL LYMPHOMA; PRIORITY JOURNAL; PROGNOSIS; PROGRESSION FREE SURVIVAL; SEX DIFFERENCE; T CELL LYMPHOMA; TREATMENT OUTCOME; TREATMENT RESPONSE;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COMBINED MODALITY THERAPY; CYCLOPHOSPHAMIDE; DISEASE-FREE SURVIVAL; DOXORUBICIN; FEMALE; HUMANS; LYMPHATIC DISEASES; LYMPHOMA, T-CELL, PERIPHERAL; MALE; MEDIASTINAL DISEASES; MIDDLE AGED; PREDNISONE; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; SERUM ALBUMIN; SEX FACTORS; STEM CELL TRANSPLANTATION; TRANSPLANTATION, AUTOLOGOUS; TREATMENT OUTCOME; VINCRISTINE;

EID: 72949091680     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.3109/10428190903318311     Document Type: Article

References (21)

1. Armitage J, Vose J, Weisenburger D. International peripheral T-cell and natural killer/T-cell lymphoma study: pathology findings and clinical outcomes. J Clin Oncol 2008;26:4124-4130.
2. Gisselbrecht C, Gaulard P, Lepage E, et al. Prognostic significance of T-cell phenotype in aggressive non-Hodgkin's lymphomas. Groupe d'Etudes des Lymphomes de l'Adulte (GELA). Blood 1998;92:76-82.
3. Lopez-Guillermo A, Cid J, Salar A, et al. Peripheral T-cell lymphomas: initial features, natural history, and prognostic factors in a series of 174 patients diagnosed according to the R.E.A.L. Classification. Ann Oncol 1998;9:849-855.
4. Swerdlow S, Campo E, Harris N, et al. WHO classification of tumours of haematopoietic and lymphoid tissues, 4th ed. International Agency for Research on Cancer 2008;306-311.
5. Corradini P, Tarella C, Zallio F, et al. Long-term follow-up of patients with peripheral T-cell lymphomas treated up-front with high-dose chemotherapy followed by autologous stem cell transplantation. Leukemia 2006;20:1533-1538.
6. Mercadal S, Briones J, Xicoy B, et al. Intensive chemotherapy (high-dose CHOP/ESHAP regimen) followed by autologous stem-cell transplantation in previously untreated patients with peripheral T-cell lymphoma. Ann Oncol 2008;19:958-963.
7. A predictive model for aggressive non-Hodgkin's lymphoma. The International Non-Hodgkin's Lymphoma Prognostic Factors Project. N Engl J Med 1993;329:987-994.
8. Gallamini A, Stelitano C, Calvi R, et al. Peripheral T-cell lymphoma unspecified (PTCL-U): a new prognostic model from a retrospective multicentric clinical study. Blood 2004; 103:2474-2479.
9. Mourad N, Mounier N, Briere J, et al. Clinical, biologic, and pathologic features in 157 patients with angioimmunoblastic T-cell lymphoma treated within the Groupe d'Etude des Lymphomes de l'Adulte (GELA) trials. Blood 2008;111: 4463-4470.
10. Kaplan EL, Meire P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958;53:457-481.
11. Ogura M, Kagami Y, Taji H, et al. Pilot phase I/II study of new salvage therapy (CHASE) for refractory or relapsed malignant lymphoma. Int J Hematol 2003;77:503-511.
12. Hasenclever D, Diehl V. A prognostic score for advanced Hodgkin's disease. International Prognostic Factors Project on Advanced Hodgkin's Disease. N Engl J Med 1998;339: 1506-1514.
13. Arcaini L, Lazzarino M, Colombo N, et al. Splenic marginal zone lymphoma: a prognostic model for clinical use. Blood 2006;107:4643-4649.
14. Ngo L, Hee SW, Lim LC, et al. Prognostic factors in patients with diffuse large B cell lymphoma: before and after the introduction of rituximab. Leuk Lymphoma 2008;49:462-469.
15. Ohshima K, Karube K, Kawano R, et al. Classification of distinct subtypes of peripheral T-cell lymphoma unspecified, identified by chemokine and chemokine receptor expression: analysis of prognosis. Int J Oncol 2004;25:605-613.
16. Yamamoto K, Tobinai K, Utsunomiya A, et al. Phase I study of KW-0761, a defucosylated anti-CCR4 antibody, in relapsed patients with adult T-cell leukemia-lymphoma or peripheral T-cell Lymphoma: updated results. Blood 2008; 112:1007a.
17. Dupuis J, Emile JF, Mounier N, et al. Prognostic significance of Epstein-Barr virus in nodal peripheral T-cell lymphoma, unspecified: a Groupe d'Etude des Lymphomes de l'Adulte (GELA) study. Blood 2006;108:4163-4169.
18. Attygalle AD, Kyriakou C, Dupuis J, et al. Histologic evolution of angioimmunoblastic T-cell lymphoma in consecutive biopsies: clinical correlation and insights into natural history and disease progression. Am J Surg Pathol 2007;31: 1077-1088.
19. Bossard C, Belhadj K, Reyes F, et al. Expression of the granzyme B inhibitor PI9 predicts outcome in nasal NK/T-cell lymphoma: results of a Western series of 48 patients treated with first-line polychemotherapy within the Groupe d'Etude des Lymphomes de l'Adulte (GELA) trials. Blood 2007;109: 2183-2189.
20. Asano N, Suzuki R, Kagami Y, et al. Clinicopathologic and prognostic significance of cytotoxic molecule expression in nodal peripheral T-cell lymphoma, unspecified. Am J Surg Pathol 2005;29:1284-1293.
21. Nakamura S, Suchi T. A clinicopathologic study of node-based, low-grade, peripheral T-cell lymphoma. Angioimmunoblastic lymphoma, T-zone lymphoma, and lymphoepithelioid lymphoma. Cancer 1991;67:2566-2578.